Introduction
The antibacterial spectra of erythromycin and lincomycin are very similar. The only significant differences are the greater sensitivity to erythromycin of Neisseria and Haemophilus species, and the sensitivity to lincomycin of erythromycinresistant strains of Staphylococcus aureus. In general, organisms tend, when sensitive to both antibiotics, to be more sensitive to erythromycin, which is therefore preferred, except possibly for the treatment of staphylococcal osteomyelitis.
Clindamycin (7-chlor-lincomcyin) is a derivative of lincomycin that is much more active than the parent compound (Meyers, Kaplan, and Weinstein, 1969) . This led to the present in-vitro comparison of the activity of erythromycin, lincomycin, and cindamycin against organisms recently isolated from clinical material.
It should be noted that clindamycin is called clinimycin in the early American literature (McGehee, Smith, Wilcox, and Finland, 1968) 
Discussion
Erythromycin and lincomycin have been compared in several previous studies, with the conclusion, usually, that erythromycin is slightly more active and is thus the more useful drug, except possibly in the treatment of osteomyelitis, for which lincomycin is preferred, but on the basis of pharmacological rather than microbiological properties (Barber and Waterworth, 1964; Geddes, Sleet, and Murdoch, 1964; McMillan, McRae, and McDougall, 1967; Sanders, 1969 In contrast, erythromycin is somewhat more active against H. influenzae and it is clearly much more active than clindamycin against Str. faecalis and N. gonorrhoeae.
As with macrolides and lincomycin, the activity of clindamycin is enhanced by increasing alkalinity. The decrease of M.I.C. for each unit rise of pH that we obtained with clindamycin was less than the tenfold decrease reported by Haight and Finland (1952) for erythromycin but similar to that reported by Barber and Waterworth (1964) for lincomycin.
The relevance of these observations depends on whether in-vivo results parallel the in-vitro results. It is already known that clindamycin is well tolerated and well absorbed, giving serum levels of the same -order as lincomycin (McGehee et al., 1968; Wagner, Novak, Patel, Chidester, and Lummis, 1968) , and that the addition of 50% plasma to media for M.I.C. determination has little effect on results, suggesting that the drug is not significantly bound to plasma proteins (McGehee et al., 1968) .
Clinical trials of clindamycin would therefore be justified in infections for which erythromycin is at present indicated. Examples are infections due to pneumococci or betahaemolytic streptococci in patients to whom penicillins cannot be given and resistant Staph. aureus infections, as this organism is so rarely resistant to clindamycin. The drug might also be useful against H. influenzae, and therefore in chronic bronchitis, if sufficiently high sputum levels can be attained. Gonorrhoea and infections due to Str. faecalis are exceptions for which clindamycin would probably be less effective than erythromycin.
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